Navigation Links
Pain and Intensity Of Post-stroke Spasticity Decreased by Botox Treatment

Final results from a multi-center study shows that repeated treatments of botulinum toxin type A over one year is well tolerated and results in a significant decrease in spasticity, pain frequency and average pain intensity in upper limbs following stroke, according to research from a neurologist at Wake Forest University Baptist Medical Center.

Significant improvements in these outcome measures indicate a better quality of life for post-stroke patients suffering from spasticity-related pain, according to the researchers who presented their findings today at the annual meeting of the American Academy of Neurology in Boston. Spasticity is a disabling condition that leaves the muscles and tendons permanently shortened and inhibits movement.

In the clinical setting, limb stiffness and pain are the most commonly reported symptoms of spasticity following a stroke, and relief of spasticity-related pain is a priority treatment goal for many patients, said Allison Brashear, M.D., professor and chairman of neurology at Wake Forest University Baptist Medical Center and head of the spasticity clinic at Wake Forest Baptist.

Our study shows that treatment with botulinum toxin type A can lessen these disabling symptoms without treatment-limiting side effects, which in turn improves the ability of stroke patients to perform such essential activities of daily living as dressing themselves, maintaining good personal hygiene, and reaching for and grasping everyday objects.

This is the largest long-term study to evaluate repeated treatment with BoNTA for post-stroke spasticity. Brashear and colleagues had reported in 2002 that one-time injections of BoNTA are safe and effective in people with wrist and finger spasticity after a stroke.

About 58 percent of stroke survivors experience post-stroke spasticity, and only 51 percent of those are receiving treatment for that condition, according to the National Stroke A ssociation.

A total of 279 patients were enrolled in the 12-month study of BoNTA to evaluate the efficacy and safety of repeated BoNTA treatments. All study participants received up to five treatments of BoNTA. For the study, the BoNTA injections were given at the elbow, wrist and fingers and/or thumbs flexor of the affected limb to block overactive nerve impulses that trigger excessive muscle contractions. Patients were assessed every six weeks for one year. Patients demonstrated a significant reduction in pain and excessive muscle tone at each follow-up. In addition, average pain intensity was significantly reduced.

Early intervention with effective therapies is absolutely vital to prevent the profound disability that afflicts many stroke patients, said Brashear. Having data to support a safe and effective profile for long-term treatment with BoNTA is significant for patients and caregivers. Many oral anti-spasticity medications are associated with systemic side effects such as sedation, mental confusion, dizziness and muscle weakness, all of which can seriously hinder rehabilitation after a stroke.


'"/>




Related medicine news :

1. Low-Intensity Exercise The Key To Losing More Pounds
2. Good Sleep Habits Could Reduce the Intensity of Migraines
3. Varying Weight Training Intensity Ups Growth Hormone in Women
4. Intensity of Rheumatoid Arthritis Significantly Reduced by Pregnancy
5. Chicken Eaters Have Decreased Risk Of Developing Colon Cancer
6. Asthma Risk Related To Decreased Fruit and Vitamin C consumption
7. Asthma Risk Related To Decreased Fruit and Vitamin C consumption
8. Decreased Vitamin D Intake among Teens Results in Decreased Lung Function
9. Secure Relationship Leads To Decreased Libido In Women
10. New antiperspirant in action - Botox does the difference
11. New Research Has Found Another Use For Botox
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... California (PRWEB) , ... June 26, 2016 , ... Pixel ... Cut Pro X. , "Film editors can give their videos a whole new perspective ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at ... on several important health care topics including advance care planning, healthcare costs and ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from PsychTests.com reveals that behind the ...
(Date:6/24/2016)... ... 2016 , ... Marcy was in a crisis. Her son James, eight, was out of control. ... and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... rocks at my other children and say he was going to kill them. If ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016 Research and ... "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" report ... In-Mold Electronics, Smart Skin, Structural Health Monitoring, ... Structural electronics involves electronic and/or electrical components ... replacing dumb structures such as vehicle bodies or ...
(Date:6/24/2016)... Research and Markets has announced the addition of ... report to their offering. ... The World Market for Companion Diagnostics covers the world market ... the report includes the following: , World ... Region (N. America, EU, ROW), 2015-2020 , World IVD ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
Breaking Medicine Technology: